Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies, highlighting ongoing operational execution and demand for ENHANZE-enabled products.
Is now the time to buy HALO? Find out in our full research report (it’s free for active Edge members).
Halozyme Therapeutics (HALO) Q1 CY2026 Highlights:
- Revenue: $376.7 million vs analyst estimates of $355.1 million (42.2% year-on-year growth, 6.1% beat)
- Adjusted EPS: $1.60 vs analyst estimates of $1.52 (5.3% beat)
- Adjusted EBITDA: $218.3 million vs analyst estimates of $214 million (57.9% margin, 2% beat)
- The company reconfirmed its revenue guidance for the full year of $1.76 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $8 at the midpoint
- EBITDA guidance for the full year is $1.17 billion at the midpoint, above analyst estimates of $1.15 billion
- Operating Margin: 49%, down from 53.4% in the same quarter last year
- Market Capitalization: $7.96 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Halozyme Therapeutics’s Q1 Earnings Call
- Jason Butler (Citizens JMP): Asked about the largest contributors among ENHANZE products post-2029 and the timeline for Hypercon deal discussions. CEO Helen Torley explained that multiple products, including OCREVUS and VYVGART, are expected to contribute significantly, and Hypercon collaborations reflect a mix of ongoing and new partner relationships.
- Brendan Smith (Cowen): Sought clarity on the timing and manufacturing steps for Hypercon Phase I clinical starts. Torley confirmed manufacturing investments are underway, with Phase I starts expected in 2027, and indicated partners will disclose targets upon trial initiation.
- Mohit Bansal (Wells Fargo): Questioned the scalability of Hypercon technology. Torley described progress with manufacturing partners like Thermo Fisher and emphasized investments to transition from clinical to commercial capacity.
- David Risinger (Leerink Partners): Inquired about the inclusion of milestones in guidance and the impact of share buybacks. CFO David Ramsay clarified that current guidance includes anticipated milestones but not the effect of the new buyback program.
- Sean Laaman (Morgan Stanley): Asked about royalty rates for upcoming ENHANZE launches and intellectual property protection. Torley stated most deals are structured for mid-single-digit royalties, with co-formulation patents extending royalty terms beyond initial expirations.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will watch (1) the pace of new ENHANZE and Hypercon clinical program initiations, (2) the commercial uptake and market share expansion of recently launched subcutaneous therapies, and (3) progress in manufacturing scale-up for Hypercon. We will also track the impact of new collaboration agreements and potential label expansions on royalty revenue trajectory.
Halozyme Therapeutics currently trades at $67.16, up from $66.41 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
